In the first 5-years after surgery, Luminal A and Luminal B breast cancer patients had better DFS when compared to TNBC and HER2 breast cancer patients, however, as to 10-year DFS, the survival curves showed that there was no significant survival difference among Luminal B, TNBC and HER2 patients (Figure 2B). This evidence concerns the gene ERBB2 and breast cancer.